Quoin Pharmaceuticals Ltd (QNRX)

$0.7207

-0.03

(-3.91%)▲

Market is closed - opens 7 PM, 05 Jun 2024

Insights on Quoin Pharmaceuticals Ltd

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 71.8% return, outperforming this stock by 158.2%

Performance

  • $0.72
    $0.77
    $0.72
    downward going graph

    0.69%

    Downside

    Day's Volatility :6.89%

    Upside

    6.25%

    downward going graph
  • $0.60
    $110.42
    $0.72
    downward going graph

    16.26%

    Downside

    52 Weeks Volatility :99.45%

    Upside

    99.35%

    downward going graph

Returns

PeriodQuoin Pharmaceuticals LtdIndex (Russel 2000)
3 Months
-74.14%
0.0%
6 Months
-84.28%
0.0%
1 Year
-86.41%
0.0%
3 Years
-99.96%
-22.6%

Highlights

Market Capitalization
2.8M
Book Value
$5.74
Earnings Per Share (EPS)
-6.66
Wall Street Target Price
5.48
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-44.03%
Return On Equity TTM
-132.92%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-9.3M
Diluted Eps TTM
-6.66
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.55
EPS Estimate Next Year
-1.83
EPS Estimate Current Quarter
-0.76
EPS Estimate Next Quarter
-0.43

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Quoin Pharmaceuticals Ltd(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
6
Hold
1
1
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 660.37%

Current $0.72
Target $5.48

Technicals Summary

Sell

Neutral

Buy

Quoin Pharmaceuticals Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Quoin Pharmaceuticals Ltd
Quoin Pharmaceuticals Ltd
0.67%
-84.28%
-86.41%
-99.96%
-99.96%
Moderna, Inc.
Moderna, Inc.
19.0%
85.08%
12.75%
-28.27%
721.13%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.54%
31.88%
92.14%
229.83%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
36.12%
71.83%
234.04%
457.53%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
32.76%
40.6%
124.79%
171.36%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Quoin Pharmaceuticals Ltd
Quoin Pharmaceuticals Ltd
0.72
NA
NA
-2.55
-1.33
-0.44
NA
5.74
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Quoin Pharmaceuticals Ltd
Quoin Pharmaceuticals Ltd
Buy
$2.8M
-99.96%
0.72
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
721.13%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
229.83%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
457.53%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
171.36%
29.59
39.46%

Institutional Holdings

  • Susquehanna International Group, LLP

    2.12%

  • Rhumbline Advisers

    0.11%

Company Information

cellect biotechnology was founded in 2011 with a mission to become a global leader in the next generation of cellular therapies by developing innovative solutions for immune system regeneration. achieving higher selectivity, greater specificity and decreased toxicity, cellect envisions its products becoming an integral and essential part of bone marrow transplantation (bmt), as well as integrated into many aspects of regenerative medicine.

Organization
Quoin Pharmaceuticals Ltd
Employees
4
CEO
Dr. Michael Myers Ph.D.
Industry
Miscellaneous

Discover More

FAQs